Sequential research-related biopsies in phase I trials: Acceptance, feasibility and safety

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1301-1306

  Gomez Roca, C A ^a   Lacroix, L ^a   Massard, C ^a   De baere, T ^a   Deschamps, F ^a   Pramod, R ^a   Bahleda, R ^a   Deutsch, E ^a   Bourgier, C ^a   Angevin, E ^a   Lazar, V ^a   Ribrag, V ^a   Koscielny, S ^a   Chami, L ^a   Lassau, N ^a   Dromain, C ^a   Robert, C ^a   Routier, E ^a   Armand, J P ^b   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Biopsy; Cancer; Early clinical trials; Phase I; Research biopsies; Sequential biopsies

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER RESEARCH; CLINICAL EVALUATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA SEQUENCE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PAIN; PATIENT ATTITUDE; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMOTHORAX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN BIOPSY; SKIN BLEEDING; TUMOR BIOPSY; UTERUS BLEEDING;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BIOMEDICAL RESEARCH; BIOPSY; CLINICAL TRIALS, PHASE I AS TOPIC; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SAFETY; SKIN; YOUNG ADULT;

EID: 84860467379     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr383     Document Type: Article

References (18)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
2. Goulart BH, Clark JW, Pien HH et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007; 13: 6719-6726.
3. Carden CP, Sarker D, Postel-Vinay S et al. Can molecular biomarker-based patient selection in phase I trials accelerate anticancer drug development? Drug Discov Today 2010; 15: 88-97.
4. Tan DS, Thomas GV, Garrett MD et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009; 15: 406-420.
5. Arkenau HT, Barriuso J, Olmos D et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009; 27: 2692-2696.
6. Italiano A, Massard C, Bahleda R et al. Treatment outcome and survival in participants of phase I oncology trials carried from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 2008; 19: 787-792.
7. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-1610.
8. Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-4316.
9. Fasolo A, Sessa C. Translational research in phase I trials. Clin Transl Oncol 2009; 11: 580-588.
10. Lassau N, Chebil M, Chami L et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation for antiangiogenic treatment. Target Oncol 2010; 5: 53-58.
11. Locatelli G, Bosotti R, Ciomei M et al. Trancriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol Cancer Ther 2010; 9: 1265-1273.
12. Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28(7): 1181-1189.
13. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16: 1745-1755.
14. Sparchez Z, Radu P, Zaharia T et al. Contrast enhanced ultrasound guidance: a new tool to improve accuracy in percutaneous biopsies. Med Ultrason 2010; 12: 133-138.
15. Peppercorn J, Shapira J, Collyar D et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 2010; 28: 2635-2640.
16. Agulnik M, Oza AM, Pond GR et al. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 2006; 24: 4801-4807.
17. Dowlati A, Haaga J, Remick SC et al. Sequential tumor biopsies in early phase, clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001; 7: 2971-2976.
18. Brown AP, Wendler DS, Camphausen KA et al. Performing non diagnostic research biopsies in irradiated tissue: a review of scientific, clinical and ethical considerations. J Clin Oncol 2008; 26: 3987-3994.